(P081) An Analysis of Soft Tissue Anatomy and Tracking of the Prostate Using Transperineal Ultrasound

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Transperineal ultrasound allows clinicians to both detect the anatomy of the pelvis in comparable detail with MRI and appreciate intrafraction motion of the prostate and nearby critical structures in order to deliver more precise radiotherapy.

P081: Figure

Vivek N. Patel, MD, Kyle Padgett, PhD, Elizabeth Bossart, PhD, Laura Freedman, MD, Adrian Ishkanian, MD, MSc, Alan Pollack, MD, PhD, Matthew Abramowitz, MD; University of Miami Miller School of Medicine

Purpose and Objectives: Transperineal ultrasound (TPUS) imaging is capable of providing low-cost, noninvasive, and accurate anatomic imaging of the male pelvis without the use of ionizing radiation. TPUS imaging can also be utilized during external beam radiation therapy (EBRT) to aid in treatment simulation to improve visualization of soft tissue anatomy. Furthermore, this modality may be used during daily treatment delivery to localize the prostate and organs at risk (OARs) within the pelvis using native anatomic structures. Thus, this procedure would allow clinicians to perform precise intrafraction prostate-tracking. Magnetic resonance imaging (MRI) is currently employed as an adjunct to CT for enhanced soft tissue imaging. However, this study requires image fusion with CT, which can be a source of uncertainty and can not be used during treatment. In contrast, TPUS is portable and functions via benign acoustic waves, which have not been shown to affect the treatment field. Apart from these inherent advantages, TPUS imaging is more cost-effective than MRI. Given these advantageous features, we demonstrate that TPUS can identify structures of the male pelvis similar to those images gathered from an MRI prior to simulation.

Materials and Methods: In order to evaluate the effectiveness of TPUS imaging, we analyzed the data collected for seven patients as part of an institutional review board (IRB)-approved clinical trial evaluating TPUS for prostate-tracking. These patients had pathologically confirmed prostate cancer and underwent definitive treatment with external radiation. All patients had a 3T MRI prior to CT simulation. During CT simulation, the patients had a 3D TPUS (Clarity system, Elekta). These images were subsequently transferred to the Clarity Automated Fusion and Contouring Workstation (V.3.0.0.109) and were fused. Thereafter, the fused images were transferred to MIM Maestro (V.6.1.7DB04-0B) for contouring. The MRI images for all patients were contoured for the prostate and OARs, including the bladder, rectum, seminal vesicles, penile bulb, and the genitourinary diaphragm. The MRI-contoured structures were subsequently overlaid on the CT and TPUS.

Results: When comparing the contoured images on the MRI and TPUS, it is apparent that both modalities are superior to CT and similarly capable of demarcating soft tissue anatomy, such as the penile bulb (green), bladder (magenta), urethra (blue), genitourinary diaphragm (purple), prostate (red), seminal vesicles (orange), and rectum (yellow). We have provided an example of an MRI-contoured structure set overlaid on CT and US to visually portray this observation. The advantage of the TPUS during simulation and treatment can be extrapolated from these contoured images. These images may also serve as an atlas to delineate structures that can be visualized during radiotherapy. 

Conclusions: TPUS allows clinicians to both detect the anatomy of the pelvis in comparable detail with MRI and appreciate intrafraction motion of the prostate and nearby critical structures in order to deliver more precise radiotherapy.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content